echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Ascentage Pharma's EED inhibitor APG-5918 has been approved for Phase I clinical trial in China and will advance the clinical development of advanced solid tumors or hematologic malignancies

    Ascentage Pharma's EED inhibitor APG-5918 has been approved for Phase I clinical trial in China and will advance the clinical development of advanced solid tumors or hematologic malignancies

    • Last Update: 2023-01-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Ascentage Pharma (6855.
    HK) announced on November 10 that APG-5918, a class 1 embryonic ectoderm development protein (EED) inhibitor under development, has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to carry out phase I clinical trials
    for the treatment of advanced solid tumors or hematologic malignancies.
    Prior to this, the investigational variety has been approved in the United States for clinical trials for advanced solid tumors or hematological tumor indications, which is another major achievement of the company's "Sino-US dual report" strategy, basically realizing the simultaneous advancement
    of China and the United States.
    APG-5918 is the first Chinese original EED inhibitor
    to enter the clinical stage.

    This is a multicenter, open-label Phase I dose-escalation and dose-expansion clinical trial designed to evaluate the safety, pharmacokinetics, and efficacy
    of oral administration of APG-5918 in patients with advanced solid tumors or hematologic malignancies.
    Professor Xu Ruihua, President of the Chinese Society of Clinical Oncology, Director and Dean of the Cancer Center of Sun Yat-sen University, will serve as the principal investigator (PI)
    of the clinical trial.

    EZH2 is highly expressed in a variety of human cancers and promotes cancer occurrence and malignancy, and targeted methyltransferase activity to inhibit EZH2 has proven to be a successful cancer treatment strategy
    Nevertheless, secondary mutations of EZH2 can produce acquired resistance, and its homologous EZH1 also has methyltransferase activity, both of which lead to limited
    activity of EZH2 inhibitors.
    It was found that the polyproteal and EZH2 activity of the PRC2 complex are highly dependent on the scaffold and regulatory effects of EED
    Compounds that inhibit the PRC2 subunit EED can disrupt the protein-protein interaction (PPI) of EED-EZH2 and subsequently impair the function of PRC2, resulting in loss of PRC2 activity excited by H3K27me3 and preventing trimethylation of H3K27[1].

    Therefore, targeting EED protein has gained great attention
    in recent years as an alternative inactivation strategy to inhibit PRC2.

    APG-5918 is a novel potent and highly selective EED protein small molecule inhibitor with oral activity, which has a high binding affinity and has broad clinical application prospects
    in hematological tumors, solid tumors and non-tumor indications by regulating tumor tissue epigenetics and tumor microenvironment.
    APG-5918 selectively binds to the H3K27me3 domain on the EED protein, resulting in conformational changes in the EED H3K27me3 binding pocket, preventing the interaction
    of EED with the histone methyltransferase EZH2.
    Preliminary data demonstrate APG-5918's in vitro anti-tumor cell proliferation viability in multiple tumor cell lines, as well as antitumor activity
    in the PDX/CDX model of EZH2-mutated B-cell non-Hodgkin lymphoma, INI1-negative malignant rhabdomyomas, BAP1-mutated mesothelioma, and prostate cancer.

    Professor Xu Ruihua said: "Targeting the PRC2 complex protein, especially EED, may be effective in
    tumors with certain genetic characteristics.
    The EED inhibitor APG-5918 has shown clear target binding and target-related antitumor activity
    in both in vitro and in vivo tests.
    Further clinical studies are warranted to explore its efficacy

    Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said, "This is another major development following the approval of the clinical trial application for APG-5918 oncology indications in the United States, and it is also a reflection
    of Ascentage's adherence to the Sino-US dual reporting strategy and global innovation strength.
    We look forward to working with Dr.
    Xu to actively advance the clinical development of APG-5918 and benefit more patients as soon as possible
    " "



    Erokhin M, Chetverina O, Gy?rffy B, Tatarskiy V V, Mogila V, Shtil AA, et al.
    Clinical correlations of polycomb repressive complex 2 in different tumor types.
    Cancers 2021; 13:3155.

    ={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
    js?cdnversion='+~(-new Date()/36e5)];
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.